Susan H.  Alexander net worth and biography

Susan Alexander Biography and Net Worth

EVP of Biogen
Susan H. Alexander is Executive Vice President, Chief Legal Officer and Secretary of Biogen, and has served on the Executive Committee since 2006. Prior to that, from 2006 to December 2011, Ms. Alexander served as our Executive Vice President, General Counsel and Corporate Secretary. From 2003 to January 2006, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. Ms. Alexander received her B.A. from Wellesley College and her J.D. from Boston University School of Law.

What is Susan H. Alexander's net worth?

The estimated net worth of Susan H. Alexander is at least $8.49 million as of October 27th, 2022. Ms. Alexander owns 39,396 shares of Biogen stock worth more than $8,494,959 as of March 29th. This net worth estimate does not reflect any other assets that Ms. Alexander may own. Additionally, Ms. Alexander receives a salary of $2,200,000.00 as EVP at Biogen. Learn More about Susan H. Alexander's net worth.

How old is Susan H. Alexander?

Ms. Alexander is currently 67 years old. There are 4 older executives and no younger executives at Biogen. Learn More on Susan H. Alexander's age.

What is Susan H. Alexander's salary?

As the EVP of Biogen Inc., Ms. Alexander earns $2,200,000.00 per year. Learn More on Susan H. Alexander's salary.

How do I contact Susan H. Alexander?

The corporate mailing address for Ms. Alexander and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Susan H. Alexander's contact information.

Has Susan H. Alexander been buying or selling shares of Biogen?

Susan H. Alexander has not been actively trading shares of Biogen over the course of the past ninety days. Most recently, Susan H. Alexander sold 5,532 shares of the business's stock in a transaction on Thursday, October 27th. The shares were sold at an average price of $280.70, for a transaction totalling $1,552,832.40. Following the completion of the sale, the executive vice president now directly owns 39,396 shares of the company's stock, valued at $11,058,457.20. Learn More on Susan H. Alexander's trading history.

Who are Biogen's active insiders?

Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Alfred Sandrock (insider), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.

Are insiders buying or selling shares of Biogen?

During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 455 shares worth more than $101,255.70. During the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 4,183 shares worth more than $1,178,046.54. The most recent insider tranaction occured on February, 22nd when insider Priya Singhal sold 262 shares worth more than $57,962.26. Insiders at Biogen own 0.6% of the company. Learn More about insider trades at Biogen.

Information on this page was last updated on 2/22/2024.

Susan H. Alexander Insider Trading History at Biogen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/27/2022Sell5,532$280.70$1,552,832.4039,396View SEC Filing Icon  
7/25/2017Sell4,974$290.01$1,442,509.7422,258View SEC Filing Icon  
7/19/2017Sell7,758$285.00$2,211,030.0027,232View SEC Filing Icon  
See Full Table

Susan H. Alexander Buying and Selling Activity at Biogen

This chart shows Susan H Alexander's buying and selling at Biogen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biogen Company Overview

Biogen logo
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $215.63
Low: $214.00
High: $217.57

50 Day Range

MA: $229.71
Low: $212.02
High: $251.68

2 Week Range

Now: $215.63
Low: $211.01
High: $319.76

Volume

1,912,268 shs

Average Volume

1,323,656 shs

Market Capitalization

$31.34 billion

P/E Ratio

27.02

Dividend Yield

N/A

Beta

N/A